This test process has been used on a number of cancer patients often with types of cancers which have not been able to be detected early in the past eg pancreas.
This test SO FAR is on cancer sufferers, and has not been tested on the most important element, early detection. That is where AGL is so strong, though they are concentrating on breast and prostate cancers.
Difficult to know what effect on AGL's prospects. My view is that because it is so far advanced, then the increased focus on blood testing and promise from it will be beneficial for AGL.
Therefore I have it as a buy, and probably this strengthens the case for a company like Philips to take it over in the nearer future than before.
......is that there is a rise in SP following good news, and then literally the following day, there is a sell off - not vast numbers but significant in the context of this stock - which sends the SP back down again. Why anyone should sell over 20,000 shares todya is beyond my ken. Anyone else's 'ken' can explain this?
They come from all corners of the globe. Loads and loads of medical centres.
They come with benefits which can be covered by 3 simple advantages - non-invasive (and you only have to speak to someone who has had an invasive biopsy in the two key areas this company is focusing on - breast cancer and prostate cancer - to understand what a benefit that is!); ever increasing value of information to help tailor specific treatments to individual cancer patients; and last but not least there are huge savings to be made from non-invasive biopsy and savings on inappropriate treatments.
Angle have recently been teaming up with others - either by relatively small acquisitions - or more importantly by specific agreements with larger organizations to help market the products mre effectively, the most recent one being Philips!
The broker - admittedly the housebroker finncap - is giving a target of around double the current price.
What's not to like?
It is amazing to me that the share price languishes where it is. It wont be for long, all IMHO of course. To anyone who wants to make some money in th next 12-24months - and I believe it will be by a takeover - then I suggest you watch the following interview, date Nov 2017. https://angleplc.com/investor-relations/media/ or go on to the website for more information under investor relations eg on several major shareholders etc
Claude et al. I have just submitted this on the company website contact point.
I hold shares in the company. Can you please advise me when commercialisation of the Parsortix process commences will the income generated be based on 'one off' from sales of the machine to hospitals/clinics etc OR a fee 'per test' OR a combination of both. Thank you
Claude. Also underwater but only from a 48p average so happy to hold as agree potential outweighs current loos level. I have still never had any informed response from anyone on my oft asked questions as to basis of future income generation I.e. One off from machine sales or fee 'per test' - which would obviously be most beneficial. Answers PLEASE anyone in the know !
That should push up the SP form today's paltry level then, shouldnt it? Currently Im a loss making holder! My strong buy is more in hope than expectation, but I do think that this company is highly underrated given the terrific value benefits of the technology.
sorry no specific reference just automatically assumed this far down the road they would have fully protected their position otherwise the company could be worthless e.g. Through industrial espionage / disgruntled ex employee etc.
Perhaps Im behind the times. I cannot remember them saying they had. I can remember some little time ago that they werw working towards patenting their approach, whatevr that means. Im an economist, not a scientist! If you have a particular reference in mind, please let me know.
..increasing their holdings as a result of the M&A activity recently surrounding AGL. Today, Fidelity, Jupiter and L&G all showing signficant increases in their % holdings. Shows great confidence in the company going forward.
Apart from upwards, where is this company going? It wouldnt surprise me if in the coming monthd, particularly if they are able to continue their what is really a fantastic record of medical achievement across a whole spectrum of cancers and of course get patent protection, then they could go through the roof on their own, with or without significant add=ons like the recent one, or be taken over at a significant premium by a major.
Patience required as always, but really on the way this time. All IMHO.
Thanks CR. I do think understanding if it will be 'one off' sales revenue or a fee 'per test' - the latter which would obviously be highly lucrative once the number of hospitals/clinics wishing to use the technology has peaked.
Yes there is a reference in the finals to the numbers of machines and the number of tests, comparing 17 and 16 but little effect on revenue. Perhaps that is a question we can put to the CEO and also Finncap who have a key objective to raise the profile of the company, dont they, to prove their worth. I will give it a thunk - deep one!
I am a shaeholder and am running at a loss, so some of the things I am saying must be read in that context. He would say that wouldnt he?
In fact there is a lot of good news going on around this compnay right now.
1. They get into bed with Quiagen, which company not only has many customers/contacts and is very much bigger than AGL, but also AGL's star system fits well into their own programme of offerings to the medical world.
2. They get a much bigger name in the NOMAD Finncap and they should do a better job of puttingAGL out th.
3.AGL continues to build up a whole host of supporters in N America and Europe in the medical world, both in terms of actual and also comparable performance. This latest Muenster result is testimony to that. These run across a whole range of prolem areas (this one is renal) though the major target areas have been reiterated as breast cancer and prostate cancer.
4.The cash raising gives them sufficient to make a significant acquisition which give them extra vertial coverage - what in normal industry we would vertical integration - to offer a suite including several levels of the process to help practitioners in this huge opportunity field - and I mean huge.
5.The extra cash also underpins the cost of the route to market, and should see them through a fair period - how long I dont know. Will they need more? Possibly, though this raising was at a very small discount to the market price.
Anyone want to disagree, or even agree? Anyone want to add any queries/question marks (or even answers to such queries/questions) that I havent mentioned?
All additionas to a sensible BB welcome!
Surely this latest information provides even greater market potential for the product??
I posed a question sometime ago asking if anyone knew the basis of future income generation I.e. Is it 'one off' income per testing machine sold or is it much more lucrative income 'per test' performed - or the icing on the case both. Any informed view please
I a man extremely disappointed with the performance of this company with what seemed to be
an exceptional product with immense potential to both save many lives and also generate significant ongoing revenues and thus shareholder value. I wish management would provide an honest update of progress and future options.
Looking at the quantity they have reduced, I would think that is a change in policy. Given the limited change in SP, I would expect that there will be a balancing movement by another major shareholder reported in the next few days.
I still frate them a strong buy given the number of pisitive changes in movement towards a strong market position which we have seen in the last few days.- albeit some time off as all these things have long time scales.
This is more like it. It was the natural way to go. Qiagen, with 500k contacts, 4500 employees around the world, a lot of associated techniques into which Angle's programme will fit nicely and established strength in marketing.
They are also saying that they will concentrate on the 2 big winners (or losers, depending on whether you are suffering from them!) breast cancer and prostatee cancer. I am surprised that the response hasnt seen a bigger jump in SP, since the fall in the last year has been substantial. What I dont know about is the list and strength of potential competitors, and I will be even more impressed when their attempt to patent their algorithm is successful.
There is always the issue with this sort of company about how long it is going to take before they reach full commercialisation, but the NOMAD and Qiagen are major steps along the commercialisation road, and not least how much extra fundraising will be needed along the way..
I am getting quite excited as well as being positive about the role this type of diagnosis can play, especially in avoiding terrible biopsies and helping reduce misdiagnoses for these terrible medical conditions.
Perhaps the machine can be compared to some other clinical equipment that have entered the market. An MRI scanner is probably far more costly ergo sold in fewer numbers. You might argue all hospitals and clinics that need to detect could afford a Parsortrix machine.
It is true that the machine if sold as a final revenue product, with perhaps some maintenance or support fee could be limited income-wise. A rental system could ensure income.
As final revenue a spitball of 10,000 units sold over 3 years at £10K each would equate to a gross profit of £100mn or £33mn per year. Support fees of £1000 per machine per year = £10mn income.
I have no idea what the unit estimates are and what if any commercial projections have been made. I believe trial machines should if not already be incorporated into the diagnostic process in oncology units. Given the unit's non invasive and uncomplex interaction with a patient it seems that this should be a process made available sooner rather than later. There can be no side effects it isn't a drug.
Claude (or any other knowledgeable board member). You seem well versed on the detail of the company. Please do you know the answer to the following two questions (assuming all approvals and patents in place)?
(1) The system uses a 'machine' to analyse the blood and isolate cancer cells. Would we 'sell' the machines or 'lease/rent' them to clinics/hospitals etc.
(2) More critically, once such machines are in place, will the company make a charge 'per test'.
This seems the critical business point I.e. Will the company generate Multiple , ongoing revenue stream which will expand and expand in both scope of cancer types and number of tests.
Thanks in advance
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.